Voyager Therapeutics Archives -

Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment

Ex-Biogen R&D head Sandrock takes the top job at Voyager

https://pharmaphorum.com/news/ex-biogen-rd-head-sandrock-takes-the-top-job-at-voyager/

Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to

Novartis puts up $1.7bn for Voyager’s gene therapy platform

https://pharmaphorum.com/news/novartis-puts-up-1-7bn-for-voyagers-gene-therapy-platform/

Al Sandrock’s shock departure from Biogen in November sparked speculation about where he would show up next, and

Biogen’s former R&D chief Al Sandrock resurfaces at Voyager

https://pharmaphorum.com/news/biogens-former-rd-chief-al-sandrock-resurfaces-at-voyager/

Sanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as

Sanofi hands back neurology gene therapy rights to Voyager

https://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/

Voyager Therapeutics